Find out how to fill up your pipeline and increase innovation. Pharma IQ is proud to provide an international, non-biased, central resource, for professionals working in early discovery and preclinical research to exchange ideas on best practice and share case studies on innovation within the area.
Pre-Clinical (Discovery and Development)
After years of resistance, the health care and pharmaceutical industries are now accelerating full steam towards the cloud. In fact, the global health care cloud computing market, valued at $4.5 billion in 2016, will reach $9.5 billion by 2020. Here are the dominant benefits that are drawing these giants to the cloud. Full Article »
Big data is turning up everywhere. In this Process Perspectives podcast, Kaare Buch Petersen, Information Architect in Global IT at Christen Hansen, a Denmark-based supplier of bioscience products to food and health industries, talks about how his company has been using big data in the development of their new products. Editor's note: read a Full Podcast »
Why are IO therapies buzzing today? If we look back at the history of cancer treatment, the survival rate was measured in months, which according to oncologists was a lot back then, because the mortality rate in most cancers was 100%. Most traditional chemotherapies were not well tolerated, because they would kill both cancerous and healthy cells, leading to major side effects such as loss of hair, nausea and vomiting, and risk of infection. Survival was sometimes better, but not much better, depending on the type of cancer and the patient's own genetic and physiological make-up. The big advantage of IO therapies is that they can target specific receptors on the cancer cells and destroy them while leaving the healthy cells alone. This will also help reduce some of the traditional side effects when healthy cells are destroyed. Full Column »
Pharma IQ revisits the compound and biobanking markets to pinpoint any shifts or new trends in the market. Full Whitepaper »